Skip to main content
. 2023 Feb 15;15:17588359231151845. doi: 10.1177/17588359231151845

Table 2.

Univariable and multivariable analyses of prognostic factors for TTF and OS in melanoma patients treated with first-line nivolumab or pembrolizumab. Gender, age, TILs, BMI, NLR, LDH, sPD-L1, sPD-1, sBTN3A1, and sBTN2A1 were evaluated in the Cox regression model.

TTF Univariable Cox regression Multivariable Cox regression
HR (95% CI) p Value HR (95% CI) p Value
Gender
(M versus F)
0.75 (0.34–1.65) NS
Age
(⩽45 versus >45 years)
0.46 (0.21–1.00) 0.04 1.13 (0.45–2.82) NS
TILs
(Absent/non-brisk versus present brisk)
0.25 (0.07–0.91) 0.03 0.25 (0.6–1.07) NS
BMI
(<25 versus ⩾25)
0.46 (0.21–1.02) 0.04 0.37 (1.15–0.89) 0.02
NLR
(⩽2.6 versus >2.6)
2.26 (1.00–5.11) 0.04 1.63 (0.60–4.36) NS
LDH
(⩽300 versus >300)
2.11 (0.96–4.63) 0.05
sPD-L1
(<1.17 versus ⩾1.17)
1.25 (0.54–2.89) NS
sPD-1
(<11.24 versus ⩾11.24)
3.62 (1.51–8.67) 0.002 4.5 (1.71–12.03) 0.002
sBTN3A1
(<9.7 versus ⩾ 9.7)
0.89 (0.34–2.00) NS
sBTN2A1
(<4.0 versus ⩾4.0)
0.44 (0.19–0.97) 0.03 0.57 (0.23–1.37) NS
OS Univariable Cox regression Multivariable Cox regression
HR (95% CI) P Value HR (95% CI) p Value
Gender
(M versus F)
0.74 (0.32–1.70) NS
Age
(⩽45 versus >45 years)
0.94 (0.41–2.12) NS
TILs
(Absent/non-brisk versus present brisk)
0.35 (0.10–1.25) NS
BMI
(<25 versus ⩾25)
0.52 (0.23–1.18) NS
NLR
(⩽2.6 versus >2.6)
2.15 (0.94–4.93) 0.06
LDH
(⩽300 versus >300)
2.54 (1.07–6.05) 0.02 1.79 (0.67–4.78) NS
sPD-L1
(<1.17 versus ⩾1.17)
1.31 (0.55–3.09) NS
sPD-1
(<11.24 versus ⩾11.24)
2.44 (1.05–5.68) 0.03 1.79 (0.67–4.78) NS
sBTN3A1
(<9.7 versus ⩾9.7)
0.85 (0.37–1.95) NS
sBTN2A1
(<4.0 versus ⩾4.0)
0.85 (0.38–1.91) NS

BMI, body mass index; CI, confidence interval; HR, hazard ratio; LDH, lactate dehydrogenase; NLR, neutrophil-to-lymphocyte ratio; OS, overall survival; sBTN, soluble butyrophilin; sPD-1, soluble programmed cell death protein 1; sPD-L1, soluble programmed cell death ligand 1; TILs, tumor-infiltrating lymphocytes; TTF, time to treatment failure.